Sign in Register

Drug class

Respiratory Syncytial Virus (RSV) Vaccine

The respiratory syncytial virus (RSV) vaccine class comprises immunobiological agents—including recombinant protein subunit and mRNA-based formulations—designed to provide active immunization against RSV. Read more about Respiratory Syncytial Virus (RSV) Vaccine

6 drugs in this class 3 manufacturers

Related classes & indications

Japanese Encephalitis VaccineVaccines · 2 prescription drugs Hepatitis B VaccineVaccines · 24 prescription drugs Respiratory Syncytial Virus Pneumonia PreventionTop indication · 11 prescription drugs

Showing 1–6 of 6 drugs

Sort

AREXVY (PF) (respiratory syncytial virus vacc. antigen/AS01E adjuvant/PF)

RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE · RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA PREVENTION

GSK

ABRYSVO (respiratory syncytial virus vaccine, preF A and B/PF)

RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE · RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA PREVENTION ·+1

Laboratories Div

AREXVY (respiratory syncytial virus vacc. antigen/AS01E adjuvant/PF)

RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE · RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA PREVENTION

GSK

AREXVY ANTIGEN COMPONENT (respiratory syncytial virus vaccine, antigen 2 of 2)

RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE · RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA PREVENTION

GSK

MRESVIA (PF) (respiratory syncytial virus vaccine, preF protein, mRNA/PF)

RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE · RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA PREVENTION

MODERNA US, INC

MRESVIA (respiratory syncytial virus vaccine, preF protein, mRNA/PF)

RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE · RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA PREVENTION

MODERNA US, INC

Filter & compare in the drug finder → Opens the drug finder with Respiratory Syncytial Virus (RSV) Vaccine preselected. Add indication or manufacturer filters there.

About Respiratory Syncytial Virus (RSV) Vaccine.

The respiratory syncytial virus (RSV) vaccine class comprises immunobiological agents—including recombinant protein subunit and mRNA-based formulations—designed to provide active immunization against RSV.

These vaccines function by presenting or encoding stabilized forms of the viral fusion (F) glycoprotein, predominantly in its prefusion conformation, to elicit neutralizing antibodies and protective cellular immune responses that inhibit viral entry and fusion into host cells.

Therapies in this class are indicated to prevent RSV-associated lower respiratory tract disease (LRTD) and its severe complications, such as pneumonia and bronchiolitis.

They are primarily utilized in older adults and individuals with underlying high-risk medical conditions, as well as administered during pregnancy to confer passive protection to infants from birth through six months of age via transplacental maternal antibodies.

fda.gov
The respiratory syncytial virus (RSV) vaccine class comprises immunobiological agents—including recombinant protein subunit and mRNA-based formulations—designed to provide active immunization against RSV They are primarily utilized in older adults and individuals with underlying high-risk medical conditions, as well as administered during pregnancy to confer passive protection to infants from birth through six months of age via transplacental maternal antibodies
fda.gov
The respiratory syncytial virus (RSV) vaccine class comprises immunobiological agents—including recombinant protein subunit and mRNA-based formulations—designed to provide active immunization against RSV
nih.gov
The respiratory syncytial virus (RSV) vaccine class comprises immunobiological agents—including recombinant protein subunit and mRNA-based formulations—designed to provide active immunization against RSV These vaccines function by presenting or encoding stabilized forms of the viral fusion (F) glycoprotein, predominantly in its prefusion conformation, to elicit neutralizing antibodies and protective cellular immune responses that inhibit viral entry and fusion into host cells
fda.gov
Therapies in this class are indicated to prevent RSV-associated lower respiratory tract disease (LRTD) and its severe complications, such as pneumonia and bronchiolitis They are primarily utilized in older adults and individuals with underlying high-risk medical conditions, as well as administered during pregnancy to confer passive protection to infants from birth through six months of age via transplacental maternal antibodies
fda.gov
Therapies in this class are indicated to prevent RSV-associated lower respiratory tract disease (LRTD) and its severe complications, such as pneumonia and bronchiolitis
cdc.gov
They are primarily utilized in older adults and individuals with underlying high-risk medical conditions, as well as administered during pregnancy to confer passive protection to infants from birth through six months of age via transplacental maternal antibodies